PLUS THERAPEUTICS Inc.
PLUS THERAPEUTICS Inc. (PSTV): 6 pipeline candidates · ~7 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.4 months
D/E 0.67 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for PLUS THERAPEUTICS Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$34.5M
Cash
$3.0M
Quarterly Burn
$6.2M
Runway
7.4 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| 186rnl | Phase 1 |
| 188rnl-bam | Preclinical |
| reyobiq | Phase 2 |
| rhenium obisbemeda | Phase 2 |
| rhenium-186 nanoliposome | Phase 1 |
| the needle destroyer | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$430
| Holder | Shares | Value |
|---|---|---|
| sbi securities co., ltd. | 2,644 | $430 |
Frequently asked questions
How many drug candidates are in PLUS THERAPEUTICS Inc.'s pipeline?
PLUS THERAPEUTICS Inc. (PSTV) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PLUS THERAPEUTICS Inc.'s lead drug candidate?
PLUS THERAPEUTICS Inc.'s most advanced tracked candidate is 186rnl (Phase 1) for Leptomeningeal Metastasis.
What is PLUS THERAPEUTICS Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PLUS THERAPEUTICS Inc. has approximately 7.4 months of cash runway.
What is PLUS THERAPEUTICS Inc.'s market capitalization?
PLUS THERAPEUTICS Inc.'s market capitalization is approximately $34.5M.
Who is the CEO of PLUS THERAPEUTICS Inc.?
Dr. Marc H. Hedrick M.B.A., M.D. is the chief executive officer of PLUS THERAPEUTICS Inc. (PSTV).
Get the full picture on PLUS THERAPEUTICS Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.